Obesity: Difference between revisions

243 bytes removed ,  1 month ago
no edit summary
No edit summary
No edit summary
Line 39: Line 39:
Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. The New England journal of medicine. Dec 15 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601
Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. The New England journal of medicine. Dec 15 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601


Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252.
[https://pubmed.ncbi.nlm.nih.gov/35441470/ STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension]


[https://pubmed.ncbi.nlm.nih.gov/24708463/ A retrospective description of anesthetic medication dosing in overweight and obese children]
[https://pubmed.ncbi.nlm.nih.gov/24708463/ A retrospective description of anesthetic medication dosing in overweight and obese children]